The most frequent adverse events of pralsetinib included increased aspartate aminotransferase activity (31% of the patients), reduced hemoglobin concentration (22%), increased alanine aminotransferase activity (21%), constipation (21%), hypertension (20%), as well as lymphopenia and neutropenia. The gene discussed is GPT; the disease is neutropenia.